Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…
SAN FRANCISCO ‑ At this week’s BIO Investor Forum in San Francisco, there was talk of how the biotech industry has squandered money, paying for infrastructure when it should have been paying only for development and continuing to fund programs…
OK, you’re a biotech entrepreneur and you’ve found some interesting new technology. You’ve secured some seed funding, found some lab space and filled out all the appropriate paperwork for a business license. All’s that left to incorporate your brand new…
Back in 2008, biotech companies working on cancer vaccines were not exactly shouting it from the rooftops. In fact, most companies working in the space quietly began branding their drug candidates “immunotherapies” when they met with investors in an attempt…
Bad Behavior has blocked 832 access attempts in the last 7 days.
Join the Conversation